Exploring new frontiers: Effects of psychedelics on neurotransmitter‐regulated glucagon release in pancreatic islets
Diabetes Obesity and Metabolism December 14, 2023 DOI: 10.1111/dom.15411 via OpenAlex
Summary
AI-generated from the abstractPsychedelic substances like LSD, psilocybin, and DMT may influence glucagon release from pancreatic alpha cells by altering neurotransmitter concentrations involved in intra-islet and extra-islet signaling, an area that remains largely unexplored. This commentary addresses the unprecedented subject of how these substances could affect endocrine activity, particularly neurotransmitter-regulated glucagon release, suggesting a potential link between psychedelics and systemic metabolic functions.
Study at a glance
| Characteristics | Commentary Peer reviewed |
|---|---|
| Keywords | Glucagon Diabetes mellitus Library science Internal medicine Endocrinology |
| Key finding | Psychedelics might alter neurotransmitter concentrations involved in signaling pathways that impact glucagon release from pancreatic alpha cells. |
Abstract
Research on psychedelic substances such as lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT) is gaining momentum.1 However, the possible effects of these substances on systemic functions such as endocrine activity, particularly neurotransmitter-regulated glucagon release in pancreatic alpha cells, remain largely unexplored. This commentary aims to address the unprecedented subject of how psychedelics might alter neurotransmitter concentrations involved in both intra-islet and extra-islet signalling, thereby impacting glucagon release. [...]